Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

Area of Science:

• Virology
• Infectious Diseases
• Pharmacogenomics

Background:

• Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor used in HIV therapy.
• The emergence of drug resistance, particularly mutations in the reverse transcriptase gene, can limit the efficacy of antiretroviral drugs.
• The specific mutation patterns associated with didanosine resistance remain a subject of ongoing research and debate.

Purpose of the Study:

• To investigate the correlation between specific reverse transcriptase mutation clusters and the short-term virological response to didanosine (ddI).
• To evaluate the clinical significance of nucleoside-associated and thymidine-associated mutations in predicting didanosine's effectiveness in patients with failing regimens.

Main Methods:

• Analysis of plasma HIV RNA levels and reverse transcriptase mutations in 40 patients receiving didanosine as part of a failing antiretroviral regimen.
• Correlation analysis was performed to assess the relationship between mutation patterns and viral load reduction at week 4.

Main Results:

• A median fall of 0.67 log10 copies/ml in plasma viral load was observed at week 4.
• A significant correlation was found between the reduction in HIV RNA levels and the number of nucleoside-associated mutations (P = 0.0152).
• Similarly, a strong correlation was observed between viral load reduction and the number of thymidine-associated mutations (P = 0.0142).

Conclusions:

• Didanosine (ddI) demonstrates substantial antiretroviral activity when administered to patients with fewer than four nucleoside-associated or thymidine-associated mutations.
• The number of specific mutations serves as a predictive marker for didanosine's short-term virological efficacy.
• These findings contribute to a better understanding of HIV drug resistance mechanisms and inform treatment strategies.